Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.

Article Details

Citation
Copy to clipboard

Tillmann HL

Pradefovir, a liver-targeted prodrug of adefovir against HBV infection.

Curr Opin Investig Drugs. 2007 Aug;8(8):682-90.

PubMed ID
17668370 [ View in PubMed
]
Abstract

Metabasis Therapeutics Inc (previously Ribapharm Inc) is developing pradefovir, an oral liver-targeting prodrug of adefovir developed using its HepDirect technology, for the potential treatment of HBV infection. Phase II clinical trials of pradefovir have been completed.

DrugBank Data that Cites this Article

Drugs